With carbonic anhydrase inhibitors
Additive metabolic acidosis can increase metformin-associated lactic-acidosis risk.
Interaction evidence sourcePrescription metabolic / longevity
Prepared by the ezGLP team. Sources last checked .
Routes represented in the knowledgebase: Oral.
FDA-approved for type 2 diabetes; longevity use in healthy people is off-label and unproven. The label includes a lactic-acidosis boxed warning.
No validated PubMed or DOI link is currently curated for this entry.
Common or reported: diarrhea, nausea, vomiting, gas, abdominal discomfort, headache.
Serious or important: lactic acidosis, vitamin B12 deficiency.
Safety evidence sourceThese are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
Additive metabolic acidosis can increase metformin-associated lactic-acidosis risk.
Interaction evidence sourceReduced renal metformin clearance can increase exposure and lactic-acidosis risk.
Interaction evidence sourceAlcohol potentiates metformin's effect on lactate metabolism and increases lactic-acidosis risk.
Interaction evidence sourceLong-term metformin use can reduce vitamin B12 absorption and serum B12 concentration.
Interaction evidence sourceSemaglutide, tirzepatide, and liraglutide have been studied as add-on therapy to stable metformin, with complementary glucose and weight effects in type 2 diabetes.
Interaction evidence sourceTirzepatide trialLiraglutide trialSummarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.